Skip to main content

Table 3 Univariate and multivariate analyses of significant biomarkers for OS in 84 bmCRPC-patients under Abiraterone-therapy

From: Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer

Univariate analysis Multivariate analysis
Variable HR (95 % CI) p Variable HR (95 % CI) p
PSA decline ≥ 50 % no vs. yes 4.2 (2.3–7.6) <0.001 PSA decline ≥ 50 % no vs. yes 2.8 (1.2–6.3) 0.016
No-Bouncing vs. ALP-Bouncing 3.1 (1.7–5.7) <0.001 No-Bouncing vs. ALP-Bouncing 2.0 (0.7–5.7) 0.181
ALP rising after 12 w yes vs. no 4.9 (2.7–8.9) <0.001 ALP rising after 12 w yes vs. no 1.5 (0.6–3.9) 0.412
ECOG 2 vs. 0–1 2.7 (1.4–5.0) 0.002 ECOG 2 vs. 0–1 1.4 (0.6–3.1) 0.387
PSA decline ≥ 90 % no vs. yes 3.0 (1.5–6.1) 0.003 - - -
LDH normalization no vs. yes 2.6 (1.3–5.0) 0.005 LDH normalization no vs. yes 1.8 (0.8–3.9) 0.143
LDH BL > UNL yes vs. no 2.1 (1.0–4.3) 0.048 LDH BL > UNL yes vs. no 1.2 (0.2–7.1) 0.826
Visceral Mets. yes vs. no 1.8 (0.9–3.3) 0.076 Visceral Mets. yes vs. no 1.0 (0.5–2.2) 0.076
AA post-CTX vs. pre-CTX 1.5 (0.8–2.7) 0.175 - - -
ALP BL > UNL yes vs. no 1.4 (0.8–2.5) 0.199 - - -
GS ≥ 8 vs. GS < 8 1.3 (0.7–2.4) 0.365 - - -
Lnn. Mets. yes vs. no 0.9 (0.6–1.6) 0.804 - - -